Actuate Therapeutics (ACTU)
Develops elraglusib, a GSK-3β inhibitor, for metastatic pancreatic cancer.
Something off on this page? Send us feedback.
A clinical-stage biopharmaceutical company centered on elraglusib, formerly 9-ING-41. Its main program evaluates the drug with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic ductal adenocarcinoma.
Develops elraglusib, formerly 9-ING-41, a GSK-3β inhibitor in clinical development for cancer. The central program evaluates elraglusib with gemcitabine and nab-paclitaxel against chemotherapy alone in first-line metastatic pancreatic ductal adenocarcinoma. The Actuate-1801 study previously included monotherapy escalation and chemotherapy-combination work.
Originating as a UIC and Northwestern spinout, its science arose from university researchers' work that produced 9-ING-41 and preclinical validation. UIC licensed that technology to the company. It is a clinical-development business rather than a commercial-product company, and depends on clinical and regulatory progress for elraglusib, particularly in pancreatic cancer.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.4M · Total debt $405.0K · Total assets $5.2M · Shareholders' equity $989.2K
- Revenue
- $0
- Operating income
- −$4.9M
- Net income
- −$4.9M
No dividends on record.
| Institutions61 holders · as of Mar 31, 2026 | 57.71% | 13.86M shares | |
| Insiders5 holders · as of Aug 14, 2026 | 93.36% | 22.42M shares | |
| Strategic holders1 holder · as of Jun 30, 2025 | 0.82% | 196.4K shares | |
| Adds to | 151.89% |
24.01M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 151.89%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Aaron G.L. Fletcher1Insiderdirector, 10 percent owner | 42.75% | 10.27M | 13Dfiled Jun 30, 2025 ↗ |
Aaron Glenn Louis FletcherInsider | 42.16% | 10.13M | 13Dfiled Aug 19, 2024 ↗ |
Bios Capital Management, LPInstitution | 41.85% | 10.05M | 13Fas of Mar 31, 2026 |
Voss Capital, LLCInstitution | 7.18% | 1.73M | 13Fas of Mar 31, 2026 |
Todd S. ThomsonInsiderdirector, 10 percent owner | 3.77% | 904,795 | Form 4filed Jan 7, 2026 ↗ |
| See all 25 → | |||
- Aaron G.L. Fletcher's transaction reports restate only vehicles that traded; the 2025 ownership statement (10.27M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 5, 2026 | Todd S. Thomson | director, 10 percent owner: | −280,000 | $5.80 |
- Revolution Medicines
RAS(ON) inhibitor program spanning first- and later-line metastatic PDAC
- Merck
Biomarker-selected immunotherapy for MSI-H/dMMR metastatic solid tumors
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Actuate Therapeutics | $1.38 | +5.75% | $31.1M | — | — | — | — |
| Revolution Medicines | $211.75 | +1.20% | $44.48B | — | — | — | — |
| Merck | $151.86 | +0.15% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Median | 121.3 | 17.6 | 5.6 | +5.1% |